Arecor Limited was established to exploit the extensive experience of the founders in engineering solutions for novel applications of proteins and other biologics for emerging healthcare needs. Our stabilization technology originally applied to the biopharmaceutical and diagnostic sector offering protection to biologicals against degradation during long term storage and damage caused by exposure to ionizing radiation typically used in sterilization. Arecor has substantially expanded the protein stabilization technology and successfully applied it to a wide range of biopharmaceuticals, medical devices and diagnostics, building significant partnerships with a number of major pharmaceutical and biotechnology companies.

Arecor is based at Cambridge Science Park in the United Kingdom and employs staff with expertise in protein formulation and analysis, manufacture and regulatory approval. It has extensive in-house analytical capabilities and access to the facilities of Unilever Research and Cambridge University.

Unilever Ventures is the lead investor of Arecor.